Bristol backs out of BET inhibition | ApexOnco - Clinical Trials news and analysis (oncologypipeline.com)

Thought this article mildly interesting, from last Friday; Excerpt  :

"Elsewhere, a poor financial position is arguably Zenith’s biggest handicap. The Canadian biotech has one asset in the BET inhibitor ZEN-3694, which is being trialled in various combinations across several tumour types. Cash or partners will have to be found to push forward, although it is worth noting that Merck & Co and Astellas are already on board as clinical collaborators in prostate cancer."

Then,  researched Astellas and they sunk 5.9B into a small biotech last year ; would they do it again if ZEN-3694 could be packaged with Xtandi to keep its patent fresh?

Interesting  to RVX board for financial implications to RVX ;/  anyyone know when this next trial with Astellas reads out?